Dogwood Therapeutics Secures $12.5M in Funding, Plans to Complete Enrollment in Phase 2b Trial of Halneuron for CINP

Dogwood Therapeutics has secured funding through a registered direct offering and concurrent private placement, raising approximately $12.5 million in gross proceeds. The financing provides sufficient funding for the company past the anticipated data readout for the Phase 2b HALT-CINP trial of Halneuron in chemotherapy-induced neuropathic pain patients. The trial has shown positive interim results, with patients demonstrating separation from placebo-treated patients in pain improvement. The company plans to finish enrollment by the end of July 2026, with topline results expected in the third quarter of 2026.